AbbVie Scores HCV First Under UK’s Early Access Scheme
AbbVie’s investigational hepatitis C treatment has become the latest therapy to get the green light under the UK’s early access to medicines scheme. The scheme enables patients to access the treatment ahead of it receiving an EU marketing authorization.
You may also be interested in...
AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe this week – but AbbVie's drug is the one to watch as analysts have dubbed it a potential blockbuster.
Among products that are due for a go/no-go recommendation by the European Medicines Agency this week are new drugs for conditions such as cancer, multiple sclerosis, mastocytosis, HIV and hepatitis C.
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.